Centro de Estudios Clínicos SAGA - CECSAGA
Centro de Estudios Clínicos SAGA - CECSAGA
Antonio Varas 517, 7500653 Providencia, Región Metropolitana
Select an option
I am a doctor
I am a sponsor
Our team
Medical staff
Marcelo Garrido Salvo
Paula Guerra
Ariel Zwenger
Mauricio Rivas Quesada
Open studies
Lung cancer
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations - TROPION-Lung08 - AstraZenecaSee more
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07) - TROPION-Lung07 - AstraZenecaSee more
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) - MK-2870-019 - Merck Sharp & Dohme LLCSee more
Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01) - Merck Sharp & Dohme LLCSee more
A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01) - MK-3475-01H/KEYMAKER-U01 - Merck Sharp & Dohme LLCSee more
Non-Hodgkin Lymphoma
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006) - waveLINE-006 - Merck Sharp & Dohme LLCSee more
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010). - BELLWAVE-010 - Merck Sharp & Dohme LLCSee more
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010) - waveLINE-010 - Merck Sharp & Dohme LLCSee more
Solid tumors
A Study of MK-1084 in KRAS Mutant Advanced Solid Tumors (MK-1084-001) - MK-1084-001 - Merck Sharp & Dohme Corp.See more
Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001) - Merck Sharp & Dohme LLCSee more
A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002) - Merck Sharp & Dohme LLCSee more
Leukemia
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006) - waveLINE-006 - Merck Sharp & Dohme LLCSee more
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010). - BELLWAVE-010 - Merck Sharp & Dohme LLCSee more
Colorectal cancer
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer - MOUNTAINEER-03 - Seagen Inc.See more
Endometrial Cancer
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005) - MK-2870-005 - GOG FoundationSee more
Gastroesophageal cancer
A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015) - TroFuse-015 - Merck Sharp & Dohme LLCSee more
Gastrointestinal Cancer
A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005) - REJOICE-GI01 - Merck Sharp & Dohme LLCSee more
Head and neck cancer
A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 - AHEAD-MERIT - BioNTech SESee more
Ulcerative colitis
A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001) - MK-7240-001 - Merck Sharp & Dohme LLCSee more
Urothelial cancer
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 - KEYNOTE-D74 - Seagen Inc.See more
